Navigation Links
Januvia Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Order Transferring Federal Claims Over Januvia and Pancreatic Cancer to California Federal Court
Date:8/27/2013

New York, New York (PRWEB) August 27, 2013

Januvia lawsuits continue to move forward, (http://www.thejanuvialawsuit.com/ ) following a decision by the U.S. Judicial Panel on Multidistrict Litigation to transfer all federally-filed product liability claims involving Januvia and similar diabetes drugs to a single federal court for pretrial proceedings, Bernstein Liebhard LLP reports. According to a Transfer Order dated August 26, 2013, the newly-formed multidistrict litigation will be presided over by the Honorable Anthony J. Battaglia in the U.S. District Court, Southern District of California. All of the Januvia lawsuits transferred to the proceeding accuse Merck & Co. of failing to provide doctors and patients with adequate warnings regarding a potential link between Januvia and pancreatic cancer. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452)

“Our Firm has received numerous Januvia lawsuit inquiries from individuals who were diagnosed with pancreatic cancer while using this diabetes drug. The multidistrict litigation established in California federal court will provide an efficient means for resolving what could be a large number of claims,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free legal evaluations to alleged victims of Januvia pancreatic cancer, as well as pancreatitis and thyroid cancer.

Januvia and Pancreatic Cancer
Court documents indicate that 53 product liability claims, including Januvia lawsuits, have been filed in various federal courts on behalf of patients who allege their use of type 2 diabetes medications known as incretin mimetics resulted in the development of pancreatic cancer. A multidistrict litigation, such as the one established for these claims, consolidates all lawsuits involving common questions of fact in one jurisdiction for coordinated pretrial proceedings. The aim of a multidistrict litigation is to avoid duplicative discovery and inconsistent rulings across similar lawsuits, and to conserve the resources of the court, parties and witnesses.

In recent years, incretin mimetics like Januvia have been the subject of growing concerns surrounding their potential to harm the pancreas. In 2009, a caution regarding a link between Januvia and pancreatitis – a risk factor for pancreatic cancer - was added to the drug’s label after the U.S. Food & Drug Administration (FDA) became aware of 88 instances where Januvia patients had developed acute pancreatitis.* In 2011, a study published in Gastroenterology found that use of Januvia appeared to increase the risk of pancreatitis and pancreatic cancer, while two cases of thyroid cancer were also reported in the patients who took Januvia.**

In March of this year, the FDA announced that it was investigating incretin mimetics after results from an unpublished study indicated these medications might cause pre-cancerous changes in the pancreas. While the agency has not yet been able to confirm a conclusive link between the use of such drugs and pancreatic cancer, it has said its “review is ongoing as pancreatitis and pancreatic cancer data are being collected.”*** Most recently, a report published June 10th in the British Medical Journal revealed previously unpublished data that indicated the manufacturers of incretin mimetics may have downplayed the drugs’ potential to harm the pancreas.****

Patients who have developed pancreatic cancer, thyroid cancer or pancreatitis that may be related to the use of Januvia could be entitled to compensation for medical bills, lost wages, pain and suffering and more. Learn More about the possible link between Januvia and pancreatic cancer by visiting Bernstein Liebhard LLP’s website. For more information, please call 800-511-5092.

*fda.gov/Drugs/DrugSafety/ucm343187.htm
**http://www.gastrojournal.org/article/S0016-5085%2811%2900172-7/abstract, Gastroenterology, February 21, 2011
***pharmalive.com/fda-decides-no-risk-of-pancreatic-cancer-with-diabetes-drugs, Pharmalot, July 31, 2013
****bmj.com/open-data/incretin#alternate; BMJ, June 10, 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.thejanuvialawsuit.com/

Read the full story at http://www.prweb.com/releases/januvia-lawsuit/januvia-pancreatic-cancer/prweb11065983.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Announces Addition of Januvia Cancer Resource Center
2. Pancreatic Cancer Correlation to Type 2 Diabetes Drugs Januvia and Byetta, New Studies Find Possible Connection
3. DrugRisk Adds New Pancreatic Cancer Warning for Diabetes Drug Januvia
4. Januvia Lawsuits Consultations Now Offered by the Berman Law Group, Januvia Lawyers and Compensation Experts
5. Januvia Lawsuit News: Rottenstein Law Group LLP Comments on Doctor’s Doubts About Januvia
6. Rottenstein Law Group LLP Comments on Drugmakers’ Cooperation With Safety Review of Byetta, Januvia, Victoza
7. Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics
8. Januvia Pancreatic Cancer Lawsuits: Bernstein Liebhard LLP Comments on Medical Journal’s Investigation of Incretin Mimetics
9. DrugRisk Update: Panel To Decide Fate of Januvia Lawsuits Next Week
10. New analysis shows that patients with Type 2 diabetes and mild renal impairment had similar improvement in blood sugar control and experienced less hypoglycemia with JANUVIA (sitagliptin) compared to sulfonylurea
11. Rottenstein Law Group LLP Acknowledges BMJ Study of Risks of Byetta, Januvia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders ... American Conference Institute’s 21st Drug & Medical Device Litigation Conference , taking place in ... , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice ...
(Date:12/2/2016)... ... ... over twenty-four years, Doctors on Liens has published a directory of the top ... care. When the company started in 1997, the directory was a single page focusing ... now ten-page directory features a vast array of medical specialists stretching from Sacramento ...
(Date:12/2/2016)... California (PRWEB) , ... December 02, 2016 , ... ... professionals, proudly announces the launch of its 60-day free trial program for all ... trip shipping make the offer a truly hassle free experience. , FlexiSpot’s unique ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... U.S. Surgeon ... interview with Mediaplanet, Dr. Murthy explains how he was inspired to practice medicine at ... learned that medicine is about more than making diagnoses and prescribing medicine,” he states. ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... Hills, California, will be included in the 2016 “Guide to America’s Top Plastic ... based on the amalgamation of their education, experience, and professional associations. , ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... December 2, 2016 On Thursday, the ... the Dow Jones Industrial Average edged 0.36% higher, to finish ... 0.35%. Losses were broad based as six out of nine ... research reports on the following Services equities: Myriad Genetics Inc. ... QGEN ), INC Research Holdings Inc. (NASDAQ: INCR ...
(Date:12/2/2016)... 2016 The concept of rare diseases and the ... this sector has been taking shape in Europe ... aspects and initiatives related to orphan medicinal products have been ... of member states individually. Many member states in the EU ... of orphan medicinal products, the result of which took the ...
(Date:12/2/2016)... 1, 2016 Around the corners of world, ... each habitable land present over earth. Cancer has become ... in a life time this is because of the ... now. Given the steady increase in global cancer incidence ... spiraling healthcare costs of treatment, there is increasing interest ...
Breaking Medicine Technology: